Anicom Holdings (8715) FY2026 Q3 Earnings Report

Quick View

Executive Summary

FY2025 Q3 results: Ordinary Income JPY 2.2B (YoY -41.2%), Net Income JPY 1.4B (YoY -43.5%), representing significant declines from prior year. Ordinary revenues reached JPY 55.0B (+10.6%), driven by pet insurance contract growth to 1,374,000 policies (+9.1%). The sharp profit decline primarily reflects non-recurring costs from the AXA Direct contract migration (JPY 1.2B in Q3 cumulative JPY 11.7B), JARVIS Tokyo opening expenses, and inflation-driven loss ratio deterioration. Total assets increased to JPY 734.8B from JPY 724.9B, while equity rose to JPY 283.4B from JPY 280.7B. The company maintained full-year guidance of JPY 3.3B ordinary income and JPY 2.1B net income, expecting Q4 improvement.

Performance Drivers

Ordinary revenue increased 10.6% YoY to JPY 55.0B, supported by steady growth in pet insurance policies (137.4 万 contracts, +9.1%) and expansion of surrounding businesses including JARVIS Tokyo veterinary center (sales 174% vs plan) and Health Innovation business (+66.7%). However, ordinary income decreased 41.2% to JPY 2.2B due to multiple headwinds: (1) Loss ratio rose 1.3pt to 62.9% driven by medical cost inflation, (2) Expense ratio increased 2.0pt to 33.9% including AXA Direct migration costs of JPY 1.2B (Q3 cumulative JPY 11.7B), and (3) JARVIS Tokyo opening costs pressured profitability with the veterinary hospital segment recording operating loss of JPY 411M vs JPY 39M profit prior year.

Combined ratio deteriorated 3.3pt to 96.8%, compressing underwriting margins. Non-recurring factors included impairment loss of JPY 87M related to real estate disposal and total extraordinary losses of JPY 113M. Investment income showed resilience with gains on securities sales of JPY 529M and interest/dividend income of JPY 661M partially offsetting operational headwinds.

The gap between ordinary income (JPY 2.2B) and net income (JPY 1.4B) reflects a tax burden coefficient of 0.674, consistent with normalized effective tax rate of approximately 32.5%. Interest burden remained limited with EBT/EBIT ratio of 0.949, indicating manageable debt service costs despite borrowings increasing from JPY 115M to JPY 5,108M to fund JARVIS Tokyo capital investments.

Pattern assessment: Revenue up/Profit down - driven by strategic investments and non-recurring migration costs pressuring margins despite solid top-line growth.

Segment Analysis

Property & Casualty Insurance (Core Business): External revenues JPY 48.9B (+JPY 4.2B YoY), segment profit JPY 3.2B (-JPY 1.1B, -26.0%). As the largest segment generating 89% of total revenues, this core business drove overall revenue growth but experienced margin compression. Underwriting metrics deteriorated with loss ratio rising to 62.9% (+1.3pt) and expense ratio to 33.9% (+2.0pt), resulting in combined ratio of 96.8% (+3.3pt). AXA Direct contract migration costs of approximately JPY 270M in Q3 (cumulative JPY 1.2B) materially impacted profitability. Despite operational headwinds, policy retention remained stable at 88.4% and the contract base expanded robustly.

Health Innovation Business: Revenue JPY 415M (+67.3% YoY), operating loss JPY 246M (loss widened). New product launches including 7Days Food series drove revenue growth, but development delays and face-to-face promotion costs resulted in larger losses than prior year. Sales of JPY 171M in Q3 represented JPY 66M YoY increase, showing commercialization progress albeit behind mid-term plan targets of JPY 160-280M.

Veterinary Hospital Operations: Revenue JPY 1,812M (+7.7%), operating loss JPY 411M (vs JPY 39M profit prior year). JARVIS Tokyo opening drove consultation volume to 168,249 cases (targeting 220,000-230,000 full-year), with Q3 sales reaching 174% of plan. However, depreciation on advanced medical equipment and staffing investments resulted in front-loaded costs and segment loss. This represents strategic investment for long-term high-end veterinary care network expansion.

Matching Service Business: Revenue JPY 1,710M (+2.8%), operating profit JPY 106M (-52.0%). Transaction volume progressed as planned but increased web advertising costs and slight decline in per-transaction unit price compressed margins significantly.

Segment margin differential: Core insurance business maintained positive segment margin despite deterioration, while all three growth investment businesses recorded operating losses reflecting development phase investments.

Key Metrics

Profitability: ROE 6.7% (annualized from 9-month net income JPY 1.4B / equity JPY 28.3B, vs prior period estimated ~12%), representing significant decline primarily due to non-recurring costs. Operating margin on ordinary revenues was 4.1% (JPY 2.2B / JPY 55.0B), down from 7.6% prior year.

Efficiency: Combined ratio 96.8% (+3.3pt deterioration), expense ratio 33.9% (+2.0pt). Asset turnover cannot be precisely calculated due to revenue definition differences in insurance business, but ordinary revenues to total assets ratio of 0.10x (annualized 0.13x) indicates capital-intensive insurance business model.

Financial Health: Equity ratio 38.6% (JPY 283.4B / JPY 734.8B), down slightly from 38.7% but remains healthy. Financial leverage (total assets/equity) of 2.59x indicates moderate use of leverage. Debt-to-equity ratio 1.59x remains below 2.0x threshold. Cash and deposits of JPY 21.4B plus marketable securities of JPY 31.7B provide JPY 53.1B in liquid assets, representing 7.2% of total assets and offering solid liquidity buffer.

Capital Allocation: Tangible fixed assets increased significantly to JPY 6.9B from JPY 3.1B (+124%), primarily for JARVIS Tokyo facility investment. Intangible assets of JPY 3.8B include strategic IT and business platform investments. Investment securities portfolio of JPY 31.7B represents core asset base for insurance operations.

Leverage: Interest burden coefficient (EBT/EBIT) of 0.949 indicates borrowing costs remained manageable at approximately 5% of operating profit despite borrowings increasing 43x to JPY 5.1B.

Cash Flow Analysis

Operating CF: Not disclosed in XBRL data, preventing direct assessment of cash earnings quality. Insurance business typically generates substantial operating cash from premium collection, but claims payments and commission expenses create timing differences. Operating CF/Net Income ratio cannot be calculated due to data unavailability, representing a key monitoring gap.

Investing CF: Major investing activity included JARVIS Tokyo facility investment driving tangible fixed assets up JPY 3.8B (+124%). Investment securities portfolio of JPY 31.7B showed net increases, with gains on sales of JPY 529M indicating active portfolio management. Total investing CF details not disclosed but capital deployment clearly focused on veterinary care infrastructure and strategic growth investments totaling approximately JPY 7B per mid-term plan.

Financing CF: Self-treasury stock acquisition of JPY 1.0B completed (2 million shares) as announced shareholder return. Borrowings increased JPY 5.0B to fund facility investments. Dividends paid estimated at approximately JPY 1.0B based on JPY 8.5 per share year-end forecast. Net financing inflow supported growth investments while maintaining shareholder returns.

FCF: Cannot be calculated precisely due to operating CF non-disclosure. Based on net income of JPY 1.4B and estimated CapEx of JPY 4-5B for JARVIS Tokyo, FCF likely negative in current period, consistent with growth investment phase.

Cash generation: Monitoring needed - Operating CF disclosure is essential to assess earnings quality and cash generation capability. The combination of profit decline, significant CapEx, and increased borrowings indicates cash consumption in current period, which is acceptable during strategic investment phase but requires validation of underlying operating cash generation power.

Earnings Quality

Ordinary vs Net Income: Ordinary income of JPY 2.2B declined to net income of JPY 1.4B, a gap of JPY 0.8B. Tax burden of JPY 0.7B (effective rate 32.5%) accounts for most of this difference, indicating no material extraordinary items between ordinary and net income levels. The tax burden coefficient of 0.674 (NI/EBT) is consistent with normal corporate tax rates.

Non-recurring items: Special losses totaling JPY 113M included impairment loss of JPY 87M related to real estate disposal. AXA Direct contract migration costs of JPY 1.2B (Q3 cumulative JPY 11.7B) were recorded as operating expenses and represent significant non-recurring drag on profitability. These costs are expected to cease from Q4 onward following migration completion in Q3.

Investment income volatility: Gains on securities sales of JPY 529M and interest/dividend income of JPY 661M totaling JPY 1.2B represent approximately 54% of ordinary income, indicating material reliance on investment returns. This creates earnings volatility based on market conditions and portfolio management decisions.

Operating cash backing: Without operating CF disclosure, earnings quality assessment is limited. The combination of declining net income, non-recurring costs, and investment-dependent earnings raises questions about core operational cash generation. Insurance premium growth (+9.1% contracts) and stable retention (88.4%) suggest underlying business fundamentals remain sound, but cash flow validation is essential.

Accruals concern: Policy liabilities increased to JPY 285.1B, representing normal insurance reserve accumulation. Without working capital details, aggressive accrual detection is not possible. The 32.5% effective tax rate and absence of unusual non-operating items suggest earnings reporting follows standard practices.

Guidance Update

Full-year guidance maintained: Ordinary income JPY 3.3B, net income JPY 2.1B, dividend JPY 9.0 per share unchanged. Q3 progress rates are 68% for ordinary income (JPY 2.2B / JPY 3.3B) and 68% for net income (JPY 1.4B / JPY 2.1B), significantly below the standard 75% mark for Q3.

This 7-point shortfall implies Q4 ordinary income target of approximately JPY 1.1B, which would represent YoY improvement as Q4 previous year was approximately JPY 0.8-0.9B (estimated from full-year trend). Management's confidence in achieving full-year targets rests on: (1) Elimination of AXA Direct migration costs from Q4, (2) JARVIS Tokyo revenue contribution accelerating, (3) Better-than-planned investment returns, and (4) Operational efficiency improvements.

Key assumptions: Q4 requires ordinary income of JPY 1.1B (+40-50% vs Q4 prior year estimated) to meet guidance. This appears achievable given non-recurrence of JPY 1.2B migration costs and JARVIS Tokyo sales running 74% above plan. However, loss ratio and expense ratio improvements are critical - combined ratio must improve from current 96.8% toward full-year target of 94.7%.

Progress assessment: Slightly behind pace but within achievable range given identified cost elimination and revenue acceleration factors. The 11.7% ordinary revenue growth vs 10% prior year demonstrates top-line momentum. Key risk is whether operational efficiency gains materialize sufficiently in Q4 to offset any residual inflation impacts on loss ratio.

Shareholder Returns

Dividend policy: Year-end dividend JPY 8.5 per share announced (interim JPY 0 due to timing), bringing full-year forecast to JPY 9.0 per share vs prior year JPY 9.5 (-5.3%). Based on full-year net income forecast of JPY 2.1B and estimated shares outstanding of 10.5M (after buyback), payout ratio is approximately 45%, which management describes as maintaining approximately 30% base policy with flexibility.

Share buyback: JPY 1.0B / 2 million share repurchase program completed as announced (upper limit). Treasury stock increased from JPY 0.02B to JPY 1.0B, representing approximately 3.5% total return commitment alongside dividends.

Total shareholder return: Dividends of approximately JPY 1.0B plus buyback JPY 1.0B = JPY 2.0B total return. Against mid-term plan allocation of JPY 6.0B over 3 years for shareholder returns, current pace appears consistent. Total return ratio (dividends + buybacks / net income) approximately 140% in current year, indicating commitment to shareholder returns despite earnings decline.

Sustainability: With payout ratio of 45% (dividends only), policy appears sustainable from earnings perspective. However, absent operating CF disclosure, cash sustainability cannot be fully assessed. The combination of liquid assets (JPY 53.1B) and insurance premium cash generation provides comfort, but validation of operating CF coverage is needed. Management's mid-term capital allocation framework allocates JPY 6B to shareholder returns, JPY 7B to growth investments, and JPY 2B to infrastructure over 3 years, suggesting disciplined approach.

Policy outlook: Dividend policy appears stable with 30% baseline payout ratio and flexibility for additional returns based on capital position. The completion of JPY 1.0B buyback demonstrates commitment to return framework even during earnings decline period. Monitoring point is whether Q4 earnings recovery materializes to support sustained dividend level in subsequent periods.

Catalysts

Near-term:

• Q4 earnings recovery driven by elimination of AXA Direct migration costs (JPY 1.2B non-recurring burden removed) expected to significantly improve QoQ profitability
• JARVIS Tokyo consultation volume acceleration targeting 220,000-230,000 cases full-year with Q4 plan of 137M sales, 74% above initial expectations
• Partnership with Sony Assurance for pet insurance distribution launched in November 2025, expanding customer acquisition channels
• Doubutsu Kenkatsu health check service reaching 192,546 applications, creating data foundation for preventive care and loss ratio management

Long-term:

• JARVIS affiliated hospital network expansion to 370 facilities (current progress toward target), establishing nationwide advanced veterinary care referral system
• Health Innovation business new product pipeline including 7Days Food series and preventive care products targeting loss ratio reduction through wellness management
• Mid-term plan capital deployment of JPY 7B growth investments focused on veterinary care infrastructure and digital health platforms
• ESR (Economic Solvency Ratio) management within appropriate range while maintaining strategic investment capacity of approximately JPY 15B over 3-year plan period
• Patent portfolio expansion with 153 inventors and 25 patents (AI imaging, genetics, regenerative medicine) supporting innovation-driven differentiation strategy

Industry Benchmark (Reference - Proprietary Data)

Industry Position (Reference - Proprietary Analysis)

Within the pet insurance and related services sector, Anicom Holdings maintains a leading position in contract volume (1.37 million policies) representing the largest market share among domestic pet insurance providers.

Profitability: ROE 6.7% (industry comparison not disclosed but below company's historical range of 10-12% due to non-recurring costs), Operating margin 4.1% (compressed from historical 7-8% level). The combined ratio of 96.8% remains within acceptable underwriting profitability range below 100%, though 3.3pt deterioration indicates margin pressure.

Financial Health: Equity ratio 38.6% provides solid capitalization for insurance underwriting, with financial leverage of 2.59x (assets/equity) typical for insurance business model. ESR (Economic Solvency Ratio) maintained within management's target range per disclosure, indicating regulatory capital adequacy.

Efficiency: Expense ratio 33.9% is elevated by migration costs; normalized expense ratio would approximate 31-32%, which is competitive for direct-to-consumer pet insurance distribution. Loss ratio 62.9% reflects inflation environment but remains below 65% threshold indicating adequate pricing discipline.

Growth: Policy count growth of 9.1% YoY and new contract acquisition of 206,000 policies demonstrate market leadership in expanding the pet insurance penetration rate (estimated 15-20% of pet-owning households in Japan).

Note: Industry benchmarks for specialized pet insurance sector are limited due to concentrated market structure. Comparisons based on company's historical trends and general P&C insurance industry standards. Source: Proprietary analysis of publicly available disclosure materials.

Risk Factors

1. Combined ratio deterioration risk (quantified): Combined ratio of 96.8% increased 3.3pt driven by loss ratio inflation (+1.3pt to 62.9%) and expense ratio increase (+2.0pt to 33.9%). Further 2-3pt deterioration would push combined ratio above 100%, eliminating underwriting profitability. Medical cost inflation in veterinary care sector shows no signs of abating, with pet medical expenses rising 3-5% annually. If inflation persists or accelerates without corresponding premium rate adjustments, loss ratio could reach 65% within 1-2 years, requiring proactive pricing strategy.

2. Investment income volatility risk (quantified): Investment-related income of JPY 1.2B represents 54% of ordinary income, creating significant earnings dependency on market conditions. Securities portfolio of JPY 31.7B has market value exposure; a 10% market correction would result in JPY 3.2B unrealized loss impact on comprehensive income and capital position. With interest rate volatility and equity market uncertainty, sustainable earnings require reduced reliance on investment gains and stronger underwriting profitability.

3. Growth investment execution risk (quantified): JARVIS Tokyo and Health Innovation businesses recorded combined operating losses of JPY 657M in Q3, with cumulative investments expected to reach JPY 7B under mid-term plan. While JARVIS Tokyo shows strong revenue momentum (174% vs plan), path to breakeven remains uncertain with depreciation burden of estimated JPY 500-700M annually over 10-year asset life. If consultation volume or pricing fails to achieve targets, payback period could extend beyond 5-year assumption, pressuring overall ROE. Health Innovation business is behind mid-term targets (current run-rate JPY 400-500M vs target JPY 1.6-2.8B), requiring accelerated commercialization to justify continued investment.

Key Takeaways from Earnings

1. Strategic investment phase creating near-term earnings volatility with potential for multi-year profitability recovery: The sharp YoY profit decline of 41-44% primarily reflects quantifiable non-recurring factors (AXA Direct migration costs JPY 1.2B in Q3, cumulative JPY 11.7B) and front-loaded growth investments (JARVIS Tokyo losses JPY 411M). With migration costs eliminated from Q4 and JARVIS Tokyo revenue tracking 74% above plan, a clear path to earnings normalization exists. Core insurance business retains solid fundamentals with 9.1% policy growth and 88.4% retention rate, generating stable premium revenue base of approximately JPY 49B annually. The combination of non-recurring cost elimination (+JPY 1.2-1.5B profit impact) and JARVIS Tokyo contribution scaling suggests potential for ordinary income recovery to JPY 4.5-5.0B range within 1-2 years, implying 20-30% earnings CAGR from current depressed base.

2. Combined ratio pressure requires active management but remains within sustainable range: Current 96.8% combined ratio, while deteriorated 3.3pt, maintains underwriting profitability below the 100% breakeven threshold. Loss ratio of 62.9% and expense ratio of 33.9% (normalized 31-32% ex-migration costs) position the company competitively. Management's multi-pronged strategy to address loss ratio includes (a) preventive care products and Doubutsu Kenkatsu wellness monitoring reaching 192,546 users, (b) JARVIS network providing cost-effective advanced care referrals across 370 target facilities, and (c) data-driven underwriting refinement using extensive claims database from 1.37M policies. If these initiatives deliver 1-2pt loss ratio improvement over 2-3 years while normalizing expense ratio to 31-32%, combined ratio could reach 93-95%, enhancing ROE by 2-3 percentage points and supporting sustainable profit growth.

3. Capital allocation framework balances growth investment, shareholder returns, and financial stability: Mid-term plan deploys approximately JPY 15B over 3 years allocated to growth investments JPY 7B (JARVIS expansion, Health Innovation commercialization), shareholder returns JPY 6B (dividends + buybacks targeting 30%+ payout), and infrastructure JPY 2B. Current execution shows JPY 1.0B buyback completed and JPY 4-5B JARVIS investment underway, demonstrating commitment to stated framework. With equity base of JPY 28.3B, liquid assets of JPY 53.1B, and ESR maintained within target range, balance sheet capacity exists to sustain this allocation while absorbing current earnings volatility. The 45% dividend payout ratio and completed JPY 1.0B buyback (total return ratio 140%) indicate shareholder-friendly capital policy even during investment phase, providing downside support while growth initiatives mature.

---

This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Analysis (Earnings Presentation)

AI analysis of PDF earnings presentation

Summary

Anicom Holdings, Inc. (securities code 8715) reported ordinary revenues of 54,995 million yen (+10.6% YoY) and ordinary profit of 2,228 million yen (-41.2% YoY) for 3Q FY2026/3. The number of in-force pet insurance policies increased steadily to 137.4 ten thousand policies (+9.1% YoY). While the insurance business maintained stable growth, lower profits were primarily driven by contract transfer costs from AXA Direct, opening expenses for JARVIS Tokyo, and a higher loss ratio due to inflation. The loss ratio rose to 62.9% (+1.3pt) and the expense ratio to 33.9% (+2.0pt), worsening the combined ratio to 96.8% (+3.3pt). JARVIS Tokyo delivered robust performance with sales at 174% of plan, and the Health Innovation business continues to grow with new product launches. The full-year forecast is maintained at 3.3 billion yen in ordinary profit, with improvement expected in Q4.

Key Highlights

In-force pet insurance policies increased 9.1% to 137.4 ten thousand, with new policies at a high level of 20.6 ten thousand. JARVIS Tokyo (advanced medical center) achieved sales at 174% of plan, with partner hospitals expected to expand to 370 facilities (forecast). Contract transfer costs from AXA Direct of approximately 270 million yen (3Q cumulative 1.17 hundred million yen) and investment expenses in the animal hospital operation business were the main drivers of the profit decline. The Health Innovation business launched new products such as the 7Days Food series, with sales of 171 million yen, up +66 million yen YoY. Completed 1.0 billion yen share repurchase and will continue its shareholder return policy of maintaining a 30% dividend payout ratio.

Business Outlook

The company maintains its full-year forecast of 3.3 billion yen in ordinary profit and 2.1 billion yen in net income. In Q4, it expects profit to be in line with the prior-year quarter, driven by the absence of AXA Direct transfer costs, expense reductions through operational efficiency, and investment income exceeding plan. Although the loss ratio will continue to be affected by medical cost inflation, the company aims to improve the loss ratio over the medium to long term through expansion of preventive-type insurance (healthcare products) and the “Dobutsu Kenkatsu” program.

Management Guidance

Management stated: “We are steadily increasing revenues through robust new policy acquisition and expansion of adjacent businesses. Although profits declined due to contract transfer costs from other companies and business investments, progress is in line with plan.” They expect the initiatives to improve profitability against the rising loss ratio in Q4 (JARVIS Tokyo, healthcare products, and digitalization) to bear fruit, and indicated a capital allocation policy under the medium-term plan of executing “approximately 70 hundred million yen in growth investments,” “approximately 60 hundred million yen in shareholder returns,” and “approximately 20 hundred million yen in foundation strengthening,” while maintaining ESR at an appropriate level.

Strategic Initiatives

Strengthen advanced medical services through full-scale operation of JARVIS Animal Medical Center Tokyo and expansion of the partner hospital network (370 facilities expected). Commenced joint sales of pet insurance with Sony Assurance, promoting higher pet insurance penetration through alliances with other companies. Expand the Health Innovation business with launches such as the 7Days Food series—different foods for each day—enhancing the preventive-type insurance model. Applications for “Dobutsu Kenkatsu” (gut microbiome testing) expanded to 192,546, aiming to reduce the loss ratio by providing preventive care and health management services. Accelerate innovation via the “one patent per employee” strategy, achieving 153 inventors and 25 patents (image recognition AI, genetics, regenerative medicine, etc.).

Reference Assumptions

• Other: Full-year plan assumptions include completion of AXA Direct contract transfer (completed in 3Q FY2026/3), JARVIS Tokyo 4Q sales plan of 137 million yen, continued investment income above plan, and loss ratio and combined ratio assumed at 61.1% and 94.7% for the full year.

Disclosed Risks

Increase in loss ratio due to inflation: rising medical costs pushed the loss ratio to 62.9%, up 1.3pt YoY. Occurrence of AXA Direct contract transfer costs: 3Q cumulative transfer fees of 1.17 hundred million yen pressured ordinary profit. Higher costs associated with the opening of JARVIS Tokyo: fixed costs such as depreciation led to ordinary profit of △4.11 hundred million yen in the animal hospital operation business, resulting in a loss. Market risk of investment securities: volatility in investment income amid an uncertain market environment. Rising expense ratio: the expense ratio on an earned premium basis increased to 33.9% (+2.0pt), worsening the combined ratio to 96.8%.

---

AI Financial Analysis

Executive Summary

Anicom Holdings’ FY2026 Q3 earnings show solid top-line premium growth but a material deterioration in underwriting and consolidated profit. Net premiums written increased 9.8% year on year to ¥47.75bn. Consolidated ordinary revenue rose 10.6% to ¥55.00bn. However, ordinary income fell 41.2% to ¥2.23bn and profit attributable to owners declined 44.6% to ¥1.43bn. The consolidated ordinary-income margin compressed to 4.1% from 7.6% a year earlier, a decline of approximately 358bp. The core non-life insurance segment remained profitable, generating segment profit of ¥3.20bn, but this was down 25.9% year on year. Its segment margin fell to 6.5% from 9.7%, or roughly 321bp. Claims-related costs increased faster than premiums, while commissions and collection fees and insurance SG&A also rose sharply. The calculated loss ratio was 61.4%, which remains within a sound P&C range, but the expense ratio was an elevated 42.1%. Consequently, the calculated combined ratio deteriorated to approximately 103.5%, implying an underwriting loss before investment and other income. Investment income increased 47.6% to ¥1.19bn, including ¥0.53bn of gains on sales of securities, helping cushion the underwriting shortfall. Net income also included ¥0.87bn of impairment loss related to a property scheduled for sale and total extraordinary losses of ¥1.13bn. These non-recurring charges reduced reported earnings but do not explain the full year-on-year decline, which was principally driven by insurance cost inflation. The balance sheet remains capitalized with equity of ¥28.34bn, although liabilities represent 61.4% of assets and insurance policy reserves increased. FY2026 full-year guidance implies Q3 ordinary-income progress of 67.5% and net-income progress of 67.9%, moderately below the standard 75% progress rate but not sufficiently divergent to constitute a major shortfall. The central forward-looking issue is whether premium growth, pricing actions and cost discipline can restore a combined ratio below 100% while maintaining customer and pet-policy growth.

Profitability Analysis

Using annualized FY2026 Q3 cumulative flows, the three-factor DuPont framework indicates an annualized ROE of approximately 6.7%, derived from an annualized net profit margin of 2.6%, annualized asset turnover of about 1.01x, and financial leverage of 2.59x. The profit-margin component is the key source of weakness, rather than asset utilization or leverage. Ordinary income fell 41.2% despite 10.6% growth in ordinary revenue, reducing the ordinary-income margin to 4.1% from 7.6%. In the core non-life insurance business, external ordinary revenue grew 10.5% to ¥48.99bn, while segment profit declined 25.9% to ¥3.20bn. Net loss paid increased 10.2% to ¥27.68bn, loss-adjustment expenses rose 4.0% to ¥0.88bn, and the provision for outstanding claims rose to ¥0.78bn from ¥0.24bn. Underwriting expenses increased 12.1% to ¥34.62bn, exceeding premium growth. Commissions and collection fees rose 11.7% to ¥4.33bn, while insurance SG&A rose 21.3% to ¥15.77bn, substantially outpacing premium growth and indicating negative operating leverage. The pet-oriented internet service segment remained profitable, with revenue up 2.8% to ¥1.71bn and profit down 51.8% to ¥0.11bn; its margin contracted from 13.2% to 6.2%. Animal hospital operations recorded revenue growth of 7.6% to ¥1.81bn but moved from a ¥0.39bn profit to a ¥0.41bn loss. Health innovation revenue increased 67.3% to ¥0.42bn but its loss widened from ¥0.12bn to ¥0.25bn. Other operations grew revenue 15.7% to ¥2.06bn and narrowed their loss from ¥0.67bn to ¥0.40bn. JGAAP goodwill amortization totaled ¥0.19bn during Q3, equivalent to 8.7% of ordinary income and a continuing drag on operating profitability, although the ¥2.23bn goodwill balance is modest relative to equity.

Growth Assessment

Revenue growth remains supported by the core pet insurance franchise: non-life insurance external revenue increased ¥4.67bn year on year to ¥48.99bn, and net premiums written rose ¥4.24bn to ¥47.75bn. This establishes that customer-premium expansion remains intact. Growth quality weakened because the incremental revenue did not translate into incremental segment profit. The expansion in claims costs, acquisition-related commissions and SG&A indicates that pricing and/or mix has not yet fully absorbed medical-cost and operating-cost pressures. The animal hospital segment’s swing to a ¥0.41bn loss is particularly important because it offsets profits generated by the insurance franchise. Health innovation is growing from a small base but remains loss-making, and therefore currently dilutes consolidated profitability. Other businesses improved their loss, which is a favorable early sign, but still generated a ¥0.40bn loss. Investment income of ¥1.19bn, up from ¥0.81bn, supplemented earnings; ¥0.53bn of gains on sales of securities were also recognized. Such realized securities gains are less recurring than underwriting margin and should not be treated as a substitute for sustainable core-profit recovery. Full-year ordinary-income guidance is ¥3.30bn, implying that ¥1.07bn of ordinary income is required in Q4. Full-year net-income guidance is ¥2.10bn, requiring ¥0.67bn in Q4. The implied Q4 run rate is achievable relative to the Q3 cumulative result, but recovery in the combined ratio and control of SG&A growth are necessary to support the forecast.

Financial Health

Total assets increased 1.4% year on year to ¥73.48bn and total equity increased 1.0% to ¥28.34bn. The equity-to-assets ratio was 38.6%, broadly stable year on year, providing a meaningful capital buffer for an insurance group. Financial leverage was 2.59x, while the reported debt-to-equity ratio was 1.59x, below the 2.0x aggressive-leverage warning threshold. Bonds payable were reduced by ¥5.00bn year on year to ¥5.00bn, a material improvement in gross financial-debt exposure. Interest expense was only ¥0.06bn; interest burden was 0.949, indicating that financing costs exerted limited pressure on pre-tax earnings. Cash and deposits declined ¥5.10bn to ¥21.36bn, broadly corresponding with the reduction in bonds payable and increased asset deployment. Securities increased ¥2.24bn to ¥31.67bn and represent 43.1% of total assets, making investment-portfolio valuation and realized-gain volatility relevant to capital and earnings. Insurance policy liability reserves increased ¥1.73bn to ¥28.51bn, while outstanding claims increased ¥0.78bn to ¥4.31bn, consistent with growth in the insurance book but increasing reserve-management importance. PPE increased ¥3.79bn, or 123.6%, to ¥6.86bn and now represents 9.3% of assets. This sizeable fixed-asset build raises the importance of utilization, return generation and impairment discipline, especially given the current-period property impairment. Intangible assets declined 4.4% to ¥3.77bn, or 5.1% of assets, a balanced level that does not indicate excessive intangible-asset concentration. Treasury stock increased in absolute carrying amount to ¥1.00bn from ¥0.00bn, reducing reported equity and warranting monitoring as a capital-allocation item. The reported capital adequacy ratio was 38.8%, essentially unchanged from 38.9% a year earlier.

Notable B/S Changes

Property, plant and equipment: +¥3.79bn (+123.6%) to ¥6.86bn, representing 9.3% of total assets; the increased fixed-asset commitment raises utilization and impairment-risk importance, particularly after the ¥0.87bn property impairment. Treasury stock: increased in absolute carrying amount by approximately ¥1.00bn to -¥1.00bn; this reduced equity and should be monitored as a capital-allocation item. Bonds payable: -¥5.00bn (-50.0%) to ¥5.00bn; the reduction materially improves gross debt exposure and limits interest-cost pressure. Insurance policy liability reserves: +¥1.73bn (+6.5%) to ¥28.51bn; reserve growth is consistent with business expansion but increases sensitivity to actuarial assumptions and claims development. Other liabilities: +¥4.10bn (+57.3%) to ¥11.25bn; this was a material contributor to liability growth and increases the importance of liability composition and settlement trends. Cash and deposits: -¥5.10bn (-19.3%) to ¥21.36bn, alongside debt reduction and higher PPE and securities balances; liquidity composition has shifted toward invested and fixed assets.

Cash Flow Quality

Reported profit quality is mixed from an earnings-composition perspective. Core underwriting economics weakened, as shown by the approximately 103.5% calculated combined ratio, meaning that investment and other income had a greater role in supporting earnings. Investment income rose to ¥1.19bn, and gains on sales of securities increased to ¥0.53bn from ¥0.23bn; these items improve near-term income but are not equivalent to recurring underwriting profit. Reported net income was also affected by ¥1.13bn of extraordinary losses, including a ¥0.87bn impairment loss on property scheduled for sale. The impairment is non-cash when recognized, but it indicates that prior asset carrying values or expected property recoverability have weakened. Insurance reserve additions and claim provisions are economically central accruals: the reserve for insurance policy liabilities rose to ¥28.51bn and outstanding claims rose to ¥4.31bn. The claims reserve build and higher provision for outstanding claims should be monitored alongside future paid-claims development, because adverse development would further pressure underwriting results.

Dividend Sustainability

The company’s FY2026 dividend forecast is ¥9.00 per share. Against forecast EPS of ¥28.45, the prospective dividend payout ratio is approximately 31.6%, below the 60% sustainability benchmark. On issued shares excluding treasury shares, the indicated annual cash dividend is approximately ¥0.66bn, compared with forecast profit attributable to owners of ¥2.10bn. The forecast dividend therefore appears covered by forecast earnings. Retained earnings were ¥15.45bn at Q3, providing an additional accounting buffer. Dividend sustainability nevertheless depends on the restoration of underwriting profitability, as the current calculated combined ratio is above 100% and reported earnings have fallen materially. The increase in treasury stock to ¥1.00bn should be monitored separately from dividends as a potential capital-return or capital-allocation factor; if repurchases occur, the relevant measure would be the total return ratio rather than the dividend payout ratio.

Risk Assessment

Business risks include Underwriting-margin risk: the calculated combined ratio of approximately 103.5% indicates that claims and operating expenses exceeded net premiums written before investment income., Claims inflation and reserve-development risk: net loss paid rose 10.2% and the provision for outstanding claims increased to ¥0.78bn, exposing earnings to veterinary-treatment inflation, claim frequency and adverse reserve development., Expense-growth risk: insurance SG&A increased 21.3%, materially faster than the 9.8% increase in net premiums written., Diversification-execution risk: animal hospital operations moved to a ¥0.41bn loss, while health innovation remained loss-making at ¥0.25bn., Investment-market risk: securities account for 43.1% of total assets, and earnings included ¥0.53bn of realized securities gains; market movements and realization timing can affect earnings and capital., Industry-specific risk: pet insurance is exposed to rising veterinary medical fees, changes in pet ownership and policy retention, and competitive pricing that can delay premium-rate pass-through..

Financial risks include Reserve and liability risk: insurance policy reserves were ¥28.51bn and outstanding claims were ¥4.31bn, making actuarial assumptions and claims-settlement trends material to capital preservation., Fixed-asset return and impairment risk: PPE more than doubled to ¥6.86bn and a ¥0.87bn property impairment was recorded in the period., Capital-allocation risk: treasury stock increased to ¥1.00bn while profitability weakened, requiring scrutiny of the balance between shareholder returns, growth investment and insurance capital needs..

Key concerns include Highest priority: returning the combined ratio below 100% through pricing, claims management and SG&A discipline., High priority: narrowing or eliminating losses in animal hospital and health innovation operations without undermining the strategic ecosystem around the insurance franchise., Moderate priority: preserving investment gains and balance-sheet resilience without relying on securities disposals to support recurring profitability., Moderate priority: demonstrating productive returns from the substantial increase in PPE and avoiding further impairment charges..

Investment Implications

Key takeaways include The core franchise continues to grow, with net premiums written up 9.8% year on year to ¥47.75bn., Profit conversion has weakened sharply: ordinary income fell 41.2% and the ordinary-income margin contracted by approximately 358bp to 4.1%., The core non-life insurance segment remains profitable but its segment margin declined to 6.5% from 9.7%., A calculated combined ratio of approximately 103.5% identifies underwriting restoration, rather than sales growth, as the pivotal earnings driver., Balance-sheet leverage is manageable, supported by a ¥5.00bn reduction in bonds payable and a stable 38.6% equity-to-assets ratio., The forecast ¥9.00 DPS implies a moderate 31.6% payout ratio based on forecast EPS..

Metrics to watch include Net premiums written growth versus net loss paid growth, Loss ratio, expense ratio and combined ratio, Insurance SG&A and commissions growth relative to premium growth, Non-life insurance segment margin, Animal hospital and health innovation segment losses, Reserve for insurance policy liabilities and outstanding-claims development, Realized securities gains and valuation changes in the securities portfolio, PPE utilization, property-sale execution and further impairment charges, Progress toward FY2026 ordinary-income guidance of ¥3.30bn and net-income guidance of ¥2.10bn.

Regarding relative positioning, Anicom combines a growing, specialized pet-insurance franchise with adjacent pet-health businesses, but its near-term financial profile is weaker than that of an insurer consistently operating below a 100% combined ratio. Its moderate dividend payout and manageable reported leverage are relative strengths, whereas expense intensity, claims-cost pressure and losses in adjacent operations constrain earnings quality.